Related Experiment Video

Updated: Jan 6, 2026

Author Spotlight: Exploring Advanced Therapeutic Targets in Osteosarcoma Through Spatial Transcriptomics
07:43

Author Spotlight: Exploring Advanced Therapeutic Targets in Osteosarcoma Through Spatial Transcriptomics

Published on: May 3, 2024

4.2K

Emerging roles and therapeutic potential of non-coding RNA in osteosarcoma: a review

Srijita Chatterjee1, Prasenjit Adhikary1, Purna Chandra Pal2

  • 1Department of Pharmaceutical Technology, Brainware University, West Bengal, 700125, India.

Medical Oncology (Northwood, London, England)
|September 23, 2025
PubMed

Insights

Non-coding RNAs (ncRNAs) play a crucial role in osteosarcoma (OS) biology, influencing tumor progression and treatment resistance. Understanding ncRNA mechanisms offers potential for new diagnostic biomarkers and therapeutic strategies for this bone cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Osteosarcoma (OS) is the most common primary malignant bone tumor.
  • OS is characterized by aggressive progression, early metastasis, and poor outcomes.
  • Conventional treatments for OS have limited efficacy.

Purpose of the Study:

  • To review the role of non-coding RNAs (ncRNAs) in osteosarcoma.
  • To explore ncRNAs as potential biomarkers and therapeutic targets for OS.

Main Methods:

  • Literature review of recent studies on ncRNAs in osteosarcoma.
  • Analysis of the regulatory functions of microRNAs, long non-coding RNAs, and circular RNAs in OS.

Main Results:

  • ncRNAs significantly regulate OS cell proliferation, migration, apoptosis, and angiogenesis.
  • Dysregulation of ncRNAs is linked to drug resistance and tumor recurrence in OS.
  • ncRNAs show potential as diagnostic and prognostic biomarkers.

Conclusions:

  • ncRNAs are critical regulators of osteosarcoma.
  • Targeting ncRNAs may lead to improved therapeutic strategies for osteosarcoma.
  • Further research into ncRNA mechanisms can advance personalized osteosarcoma management.
Keywords:
Metastasis potentialNon-coding RNAOsteosarcomaPrognosisTumor

More Related Videos

Author Spotlight: RNA FISH for Locating lncRNA-SNHG6 in Osteosarcoma Cells05:27

Author Spotlight: RNA FISH for Locating lncRNA-SNHG6 in Osteosarcoma Cells

Published on: June 16, 2023

2.2K
Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

7.6K

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.7K
Types of RNA01:20

Types of RNA

Three main types of RNA are involved in protein synthesis: messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). These RNAs perform diverse functions and can be broadly classified as protein-coding or non-coding RNA. Non-coding RNAs play important roles in regulating gene expression in response to developmental and environmental changes. Non-coding RNAs in prokaryotes can be manipulated to develop more effective antibacterial drugs for human or animal use.
RNA Performs Diverse...
8.8K
Types of RNA01:23

Types of RNA

Overview
Three main types of RNA are involved in protein synthesis: messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). These RNAs perform diverse functions and can be broadly classified as protein-coding or non-coding RNA. Non-coding RNAs play important roles in the regulation of gene expression in response to developmental and environmental changes. Non-coding RNAs in prokaryotes can be manipulated to develop more effective antibacterial drugs for human or animal use.
RNA...
72.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.1K